MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
140.91
+8.89
+6.73%
After Hours: 140.15 -0.76 -0.54% 18:44 07/17 EDT
OPEN
131.37
PREV CLOSE
132.02
HIGH
141.08
LOW
131.37
VOLUME
519.12K
TURNOVER
--
52 WEEK HIGH
141.10
52 WEEK LOW
50.49
MARKET CAP
9.06B
P/E (TTM)
-78.1184
1D
5D
1M
3M
1Y
5Y
1D
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
TipRanks · 2d ago
Protagonist Therapeutics grants inducement equity awards to new hires, sets option exercise price at $135.46
PUBT · 3d ago
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Seeking Alpha · 3d ago
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
TipRanks · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)
TipRanks · 3d ago
Protagonist Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Benzinga · 5d ago
PROTAGONIST THERAPEUTICS <PTGX.O>: BARCLAYS RAISES TARGET PRICE TO $151 FROM $119
Reuters · 5d ago
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.